Compare TG Therapeutics Inc (TGTX) vs State Street PDR S&P Retail ETF (XRT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs State Street PDR S&P Retail ETF — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while State Street PDR S&P Retail ETF trades at $84.09 (market cap $389.66M). The key difference: TG Therapeutics Inc is far larger — about 20.9× State Street PDR S&P Retail ETF's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, State Street PDR S&P Retail ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and State Street PDR S&P Retail ETF for 45 Days on average.
| TGTX | XRT | |
|---|---|---|
Market Cap | $8.16B | $389.66M |
Volume | 1,735,121 | 4,275,820 |
Sector | Health | Broad Market / Factor |
52-Week High | $59.06 | $92.35 |
52-Week Low | $26.94 | $77.28 |
Typical Hold Time | 16 Days | 45 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
XRT (SPDR S&P Retail ETF) trades at $84.09, up 1.42% with a bullish technical signal despite mixed moving averages. The ETF faces headwinds from higher interest rates and inflation impacting consumer sentiment, with Seeking Alpha noting underperformance against IVV year-to-date. Recent retail sales data shows volatility, with August rebounding 1.2% after July's unexpected 0.6% decline, creating uncertainty for the retail sector outlook.
The retail ETF's performance hinges on consumer resilience amid economic pressures, with holiday sales projections exceeding $1 trillion offering potential upside. However, persistent inflation and rate concerns present significant risks, while technical indicators show overbought conditions with RSI at 84.45 suggesting near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About State Street PDR S&P Retail ETF
XRT is an equal-weighted ETF that tracks the U.S. retail sector. It provides diversified exposure to apparel, automotive, and online retailers, including well-known names like Amazon, Target, and Costco.
Read more on XRT →
